Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It shortens T1 relaxation time, thereby increasing signal intensity on T1‑weighted magnetic resonance images, and is employed to improve visualization of the brain, spine, liver, cardiovascular system and vascular structures in adult patients.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used as a magnetic resonance imaging (MRI) contrast agent to enhance visualization of various anatomical regions.

- Brain MRI: Improves lesion detection and delineation in cerebral imaging. - Spine MRI: Enhances visualization of spinal cord and vertebral structures. - Liver MRI: Provides better contrast between hepatic lesions and normal parenchyma. - MR Angiography: Highlights vascular anatomy for accurate assessment of vessels. - Cardiac MRI: Improves delineation of myocardial tissue and cardiac chambers.

Adverse reactions may occur following administration of Multihance.

Common Side Effects: - Nausea: Mild to moderate feeling of stomach upset. - Headache: Transient headache during or after injection. - Injection site discomfort: Pain or burning at the infusion site. - Warmth sensation: Brief feeling of warmth or flushing.

Serious or Rare Side Effects: - Anaphylactic reaction: Severe allergic response requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): Rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: Marked drop in blood pressure post‑administration. - Cardiac arrest: Extremely rare but life‑threatening event.

Prior to using Multihance, several safety considerations should be observed.

- Renal function assessment: Evaluate kidney function before administration. - History of allergic reactions: Screen for prior gadolinium or contrast agent allergy. - Pregnancy: Use only if clearly needed, as safety data are limited. - Breastfeeding: Consider risk versus benefit before exposure. - Concurrent nephrotoxic drugs: Monitor renal status closely. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents; awareness of potential interactions helps mitigate risk.

Major Interactions (Avoid): - Severe renal impairment: Increases risk of nephrogenic systemic fibrosis. - Recent high‑dose iodinated contrast: May interfere with imaging interpretation. - Chelating agents: Can reduce gadolinium binding stability.

Moderate Interactions (Monitor Closely): - Loop diuretics: May affect renal clearance of the agent. - Metformin: Monitor for lactic acidosis in patients with compromised renal function. - Other gadolinium agents: Cumulative exposure may heighten adverse effect risk.